Have a feature idea you'd love to see implemented?
Let us know!
AYTU Aytu Biopharma Inc
Price (delayed)
$1.5082
Market cap
$9.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$5.72M
Highlights
AYTU's EPS has soared by 81% YoY and by 60% QoQ
The company's net income has surged by 74% YoY and by 61% QoQ
Aytu Biopharma's equity has increased by 8% QoQ but it has decreased by 7% YoY
AYTU's revenue is down by 23% YoY and by 7% QoQ
The gross profit has contracted by 16% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of AYTU
Market
Valuations
Earnings
Shares outstanding
6.15M
Market cap
$9.27M
Enterprise value
$5.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
0.12
EV/EBIT
3.35
EV/EBITDA
0.62
EV/Sales
0.08
Revenue
$75.48M
EBIT
$1.71M
EBITDA
$9.18M
Free cash flow
-$1.99M
Per share
Balance sheet
Liquidity
EPS
-$1.14
Free cash flow per share
-$0.33
Book value per share
$4.85
Revenue per share
$12.44
TBVPS
$10.65
Total assets
$115.83M
Total liabilities
$86.01M
Debt
$16.56M
Equity
$29.83M
Working capital
-$514,000
Debt to equity
0.56
Current ratio
0.99
Quick ratio
0.71
Net debt/EBITDA
-0.39
Margins
Efficiency
Dividend
EBITDA margin
12.2%
Gross margin
68.6%
Net margin
-8.3%
Operating margin
-6.2%
Return on assets
-5.1%
Return on equity
-20.6%
Return on invested capital
N/A
Return on capital employed
3.1%
Return on sales
2.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AYTU stock price
How has the Aytu Biopharma stock price performed over time
Intraday
1.22%
1 week
-2.7%
1 month
-32.37%
1 year
-38.44%
YTD
-46.89%
QTD
-35.82%
Financial performance
How have Aytu Biopharma's revenue and profit performed over time
Revenue
$75.48M
Gross profit
$51.79M
Operating income
-$4.68M
Net income
-$6.25M
Gross margin
68.6%
Net margin
-8.3%
The company's net income has surged by 74% YoY and by 61% QoQ
Aytu Biopharma's operating income has soared by 73% YoY and by 11% from the previous quarter
The company's net margin has surged by 67% YoY and by 58% QoQ
Aytu Biopharma's operating margin has surged by 65% YoY and by 4.6% QoQ
Growth
What is Aytu Biopharma's growth rate over time
Valuation
What is Aytu Biopharma stock price valuation
P/E
N/A
P/B
0.31
P/S
0.12
EV/EBIT
3.35
EV/EBITDA
0.62
EV/Sales
0.08
AYTU's EPS has soared by 81% YoY and by 60% QoQ
The P/B is 56% below the 5-year quarterly average of 0.7 and 38% below the last 4 quarters average of 0.5
Aytu Biopharma's equity has increased by 8% QoQ but it has decreased by 7% YoY
AYTU's P/S is 88% below its 5-year quarterly average of 1.0 and 40% below its last 4 quarters average of 0.2
AYTU's revenue is down by 23% YoY and by 7% QoQ
Efficiency
How efficient is Aytu Biopharma business performance
AYTU's ROS has soared by 120% QoQ and by 112% YoY
The ROA has soared by 71% YoY and by 59% from the previous quarter
The ROE has soared by 67% YoY and by 60% from the previous quarter
Dividends
What is AYTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AYTU.
Financial health
How did Aytu Biopharma financials performed over time
Aytu Biopharma's total assets is 35% higher than its total liabilities
Aytu Biopharma's total liabilities has decreased by 15% YoY and by 4.8% QoQ
Aytu Biopharma's total assets has decreased by 13% YoY
The company's debt is 44% lower than its equity
The debt to equity has grown by 12% YoY
The company's debt rose by 9% QoQ and by 2.7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.